Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Otonomy Inc    OTIC

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
12.5(c) 13.2(c) 13.7(c) 13.65(c) 13.35(c) Last
136 720 128 636 127 814 132 490 78 170 Volume
+1.21% +5.60% +3.79% -0.36% -2.20% Change
More quotes
Financials ($)
Sales 2017 3,81 M
EBIT 2017 -101 M
Net income 2017 -101 M
Finance 2017 71,0 M
Yield 2017 -
Sales 2018 22,3 M
EBIT 2018 -95,9 M
Net income 2018 -95,5 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 87,5x
Capi. / Sales2018 18,1x
Capitalization 404 M
More Financials
Company
Otonomy, Inc. engages in the research, development, and manufacture of biopharmaceutical products.The firm's portfolio includes therapeutics for diseases and disorders of the ear such as otitis media, acute otitis externa, balance disorders, Ménière's disease, tinnitus, cisplatin-induced hearing... 
More about the company
Surperformance© ratings of Otonomy Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on OTONOMY INC
04/27 Otonomy to Report First Quarter 2017 Financial Results and Provide Corporate ..
04/22 AURIS MEDICAL HOLDING AG : and Otonomy Seek FDA Approval for Drugs to Treat Ear ..
03/02 OTONOMY : reports 4Q loss
03/02 Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provi..
03/02 OTONOMY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
03/02 OTONOMY, INC. : Results of Operations and Financial Condition, Financial Stateme..
02/28 Otonomy to Present at Cowen and Company Health Care Conference
02/24 Otonomy to Report Fourth Quarter and Full Year 2016 Financial Results and Pro..
01/23 OTONOMY : Enrolls Patients for Phase 2 Trial of OTO-104 for Prevention of Hearin..
01/19 Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as ..
More news
Sector news : Bio Therapeutic Drugs
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/27Columbus Circle Investors Increases Position in Otonomy Inc $OTIC  
04/27Otonomy $OTIC Receives News Sentiment Rating of 0.24  
04/23Metropolitan Life Insurance Co. NY Has $299,000 Stake in Otonomy Inc $OTIC  
04/20Two-horse race: Auris, Otonomy seek FDA nod for inner-ear therapies
1
04/20Two-horse race: Auris, Otonomy seek FDA nod for inner-ear therapies  
More tweets
Qtime:13
News from SeekingAlpha
04/07 JAZZ PHARMA TO PLAY ITS ACQUISITION : All Notes Point To 2 Otology Companies
03/08 Otonomy (OTIC) Presents At Cowen and Company 37th Annual Health Care Conferen..
03/02 Otonomy's (OTIC) CEO David Weber on Q4 2016 Results - Earnings Call Transcrip..
03/02 Otonomy beats by $0.05, misses on revenue
01/19 Otonomy commences mid-stage study of OTO-104 to prevent hearing loss in cance..
Advertisement
Chart OTONOMY INC
Duration : Period :
Otonomy Inc Technical Analysis Chart | OTIC | US68906L1052 | 4-Traders
Full-screen chart
Technical analysis trends OTONOMY INC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 28,6 $
Spread / Average Target 114%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David A. Weber President, Chief Executive Officer & Director
Jay B. Lichter Chairman
Paul E. Cayer CFO, Chief Business & Principal Accounting Officer
Robert Michael Savel Chief Technical Officer
Dean Hakanson Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OTONOMY INC-16.04%404
AMGEN, INC.11.70%120 105
CELGENE CORPORATION7.17%96 861
GILEAD SCIENCES, INC.-4.27%89 611
REGENERON PHARMACEUTIC..5.83%41 293
VERTEX PHARMACEUTICALS..60.58%29 390
More Results